PD L1 News and Research

RSS

Multifunctional Ga-based nanoparticles combine cancer phototherapy with immunotherapy

Researchers develop a novel cancer theranostic agent that can covert light energy to heat and in turn destroy cancer cells

4 Aug 2023

Nutrition meets cancer therapy: How gut microbiome and diet impact immunotherapy success

Researchers investigated the complex relationship between gut bacteria, diet, and patient nutrition.

4 Aug 2023

Immunodiagnosis: Unleashing the potential of personalized immunotherapy

Researchers discuss the concept of immunodiagnosis and explores the potential of artificial intelligence in ID systems for precise tumor immunotherapy.

18 Jul 2023

High tumor monocyte content linked to better outcomes for esophageal cancer patients

A Ludwig Cancer Research study has discovered that the presence of relatively high numbers of immune cells known as monocytes in tumors is linked to better outcomes in esophageal cancer patients treated with a combination of chemotherapy and immunotherapy, or immunochemotherapy.

10 Jul 2023

Immunotherapy significantly improves overall survival for advanced NSCLC patients

A global study, led by UCL and UCLH and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy, when compared to single-agent chemotherapy.

6 Jul 2023

Two studies spotlight intestinal T cells that could be targeted to prevent resistance to ICB cancer therapy

Two new studies in Science and Science Immunology spotlight a group of intestinal T cells with α4β7 integrin receptors that could be targeted to prevent resistance to immune checkpoint blockade (ICB) cancer immunotherapy.

8 Jun 2023

Study assesses the safety, efficacy of using immune checkpoint inhibitors in patients with advanced kidney cancer

Patients with advanced kidney cancer are routinely given immune checkpoint inhibitors (ICIs) as first-line treatment.

5 Jun 2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances in treatments and clinical trials, how access to cancer care affects outcomes, integrative medicine and more.

5 Jun 2023

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

4 Jun 2023

Multiple sclerosis: Immune cell invasion enabled by blood-brain barrier breakdown

Blood-brain barrier breakdown in multiple sclerosis leads to immune cell infiltration into the central nervous system. Antigen presentation at the barrier promotes CD8+ T cell entry, triggering focal breakdown and hindering their invasion.

4 Jun 2023

Researchers report the role of RNA-binding protein Msi 1 to maintain breast cancer stem cells

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 9, entitled, "Increased expression of musashi 1 on breast cancer cells has implication to understand dormancy and survival in bone marrow."

16 May 2023

Study pinpoints how gut microbes boost the body's response to cancer immunotherapy

Cancer immunotherapy has transformed the treatment of many types of cancer. Yet, for reasons that remain poorly understood, not all patients get the same benefit from these powerful therapies.

4 May 2023

Spatial organization of immune cells predicts outcomes for patients with clear cell renal cell carcinoma

Outcomes for patients with clear cell renal cell carcinoma have improved over the past decade due to the approval of immunotherapies, yet still there is a subset of patients who do not respond to this type of therapy.

26 Apr 2023

Checkpoint inhibitors may not be effective lymphoma treatment when CAR T fails

For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend.

25 Apr 2023

Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.

17 Apr 2023

PD L1 News and Research

Multifunctional Ga-based nanoparticles combine cancer phototherapy with immunotherapy

Nutrition meets cancer therapy: How gut microbiome and diet impact immunotherapy success

Immunodiagnosis: Unleashing the potential of personalized immunotherapy

High tumor monocyte content linked to better outcomes for esophageal cancer patients

Immunotherapy significantly improves overall survival for advanced NSCLC patients

Two studies spotlight intestinal T cells that could be targeted to prevent resistance to ICB cancer therapy

Study assesses the safety, efficacy of using immune checkpoint inhibitors in patients with advanced kidney cancer

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

Multiple sclerosis: Immune cell invasion enabled by blood-brain barrier breakdown

Researchers report the role of RNA-binding protein Msi 1 to maintain breast cancer stem cells

Study pinpoints how gut microbes boost the body's response to cancer immunotherapy

Spatial organization of immune cells predicts outcomes for patients with clear cell renal cell carcinoma

Checkpoint inhibitors may not be effective lymphoma treatment when CAR T fails

Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes

Diverse subset of T-cell clones plays a role in the antitumor effects of immune checkpoint inhibitors

Newly found strategy used by metastasized tumors may explain why some promising immunotherapies fail

Advancements in understanding and treating breast cancer

Leaving lymph nodes intact until after immunotherapy could boost efficacy against solid tumors

Achieving immune cell checkpoint profiling

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News